The effect of the controlled release of basic fibroblast growth factor from ionic gelatin-based hydrogels on angiogenesis in a murine critical limb ischemic model

Biomaterials

Volumn 28, Issue 16, 2007, Pages 2646-2654

  Layman, Hans ^a   Spiga, Maria Grazia ^b   Brooks, Toby ^a   Pham, Si ^b   Webster, Keith A ^b   Andreopoulos, Fotios M ^a,b  

^a University of Miami College of Engineering   (United States)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

Angiogenesis; Controlled delivery; Critical limb ischemia; FGF 2; Hydrogels

Indexed keywords

AMINES; FIBROBLASTS; GENES; GROWTH KINETICS; HYDROGELS; PATIENT TREATMENT;

ANGIOGENESIS; CRITICAL LIMB ISCHEMIA; FIBROBLAST GROWTH FACTOR (FGF); PERIPHERAL ARTERY DISEASE (PAD);

MEDICAL PROBLEMS;

AMINE; BASIC FIBROBLAST GROWTH FACTOR; CARBOXYL GROUP; CD31 ANTIGEN; CYANAMIDE; GELATIN; POLYGLUTAMIC ACID; POLYLYSINE; SUCCINIMIDE DERIVATIVE;

AMIDATION; ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CAPILLARY; CELL ADHESION; CELL CULTURE; CONCENTRATION RESPONSE; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; FIBROBLAST; HYDROGEL; IMMUNOHISTOCHEMISTRY; KINETICS; LASER DOPPLER FLOWMETRY; LIMB ISCHEMIA; MOUSE; NONHUMAN; PERFUSION; PH; PRIORITY JOURNAL; SURFACE CHARGE;

ANIMALS; BIOCOMPATIBLE MATERIALS; CELL ADHESION; CELLS, CULTURED; DELAYED-ACTION PREPARATIONS; DRUG CARRIERS; EXTREMITIES; FIBROBLAST GROWTH FACTOR 2; GELATIN; HUMANS; HYDROGELS; ISCHEMIA; LASER-DOPPLER FLOWMETRY; MICE; MICE, INBRED BALB C; MOLECULAR STRUCTURE; NEOVASCULARIZATION, PHYSIOLOGIC;

MURINAE;

EID: 33847654322     PISSN: 01429612     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2007.01.044     Document Type: Article

References (33)

1. Hackam D.G., Goodman S.G., and Anand S.S. Management of risk in peripheral artery disease: recent therapeutic advances. Am Heart J 150 (2005) 35-40
2. Aranow W.S. Management of peripheral artery disease. Cardiol Rev 13 (2005) 61-68
3. Dashwood M.R., and Tusi J.C. The effect of acute ischemia on ET-1 and its receptors in patients with underlying chronic ischemia of the lower limb. Exp Biol Med 231 (2006) 802-805
4. Parsson H., Holmberg A., Siegbahn A., and Berggvist D. Activation of coagulation and fibrinolytic systems in patients with CLI is not normalized after surgical revascularization. Eur J Vasc Surg 27 (2004) 186-192
5. Comerota A.J. Endovascular and surgical revascularization for patients with intermittent claudication. Am J Cardiol 87 A (2001) 34D-43D
6. Rasmussen H.S., Rasmussen C.S., and Macko J. VEGF gene therapy for coronary artery disease and peripheral vascular disease. Cardiovasc Radiat Med 3 (2003) 114-117
7. Zhou B., Bi Y.Y., Zan Z.B., Ren H., Fang Z.H., Yu X.F., et al. G-CSF-mobilized peripheral blood mononuclear cells from diabetic patients augment neovascularization in ischemic limbs but with impaired capability. J Thromb Haemost 4 (2006) 993-1002
8. Huang P., Li S., Han M., Xiao Z., Yang R., and Han Z.C. Autologous transplantation of granulocyte-stimulating factor-mobilized peripheral blood mononuclear cells improves critical limb ischemia in diabetes. Diabetes Care 29 (2006) 478-479
9. Tabata Y., and Ikada Y. Vascularization effect of basic fibroblast growth factor released from gelatin hydrogels with different biodegradabilities. Biomaterials 20 (1999) 2169-2175
10. Gounis M.J., Spiga M.G., Graham R.M., Wilson A., Haliko S., Lieber B.B., et al. Angiogenesis is confined to the transient period of VEGF expression that follows adenoviral gene delivery to ischemic muscle. Gene Ther 9 (2006) 762-771
11. Lazarous D.F., Unger E.F., Epstein S.E., Stine A., Arevalo J.L., Chew E.Y., et al. Basic fibroblast growth factor in patients with intermittent claudication: results in phase I trial. J Am Coll Cardiol 36 (2000) 1239-1244
12. Lederman R.J., Mendelsohn F.O., Anderson R.D., Saucedo J.F., Tenaglia A.N., Hermiller J.B., et al. Therapeutic angiogenesis with recombinant fibroblast growth factor-2 for intermittent claudication (the TRAFFIC study): a randomized trial. Lancet 359 (2002) 2053-2058
13. Schumacher B., Pecher P., von Specht B.U., and Stegmann T. Induction of neoangiogenesis in ischemic myocardium by human growth factors: first clinical results of a new treatment of coronary artery disease. Circulation 97 (1998) 645-650
14. Shyu K.G., Chang H., Wang B.W., and Kuan P. Intramuscular vascular endothelial growth factor gene therapy in patients with chronic critical limb ischemia. Am J Med 114 (2003) 85-92
15. Cote M.F., Laroche G., Gagnon E., Chevallier P., and Doillon C.J. Denatured collagen as support for a FGF-2 delivery system: physicochemical characterizations and in vitro release kinetics and bioactivity. Biomaterials 25 (2004) 3761-3772
16. Tabata Y., Yamada K., Miyamoto S., Nagata I., Kikuchi H., Aoyama I., et al. Bone regeneration by basic fibroblast growth factor complexed with biodegradable hydrogels. Biomaterials 19 (1999) 807-815
17. Detillieux K.A., Cattini P.A., and Karadami E. Beyond angiogenesis: the cardioprotective potential of fibroblast growth factor-2. Can J Physiol Pharmacol 82 (2004) 1044-1052
18. Nugent M.A., and Iozzo R.V. Fibroblast growth factor-2. Int J Biochem Cell Biol 32 (2000) 115-120
19. Iwakura A., Tabata Y., Koyama T., Doi K., Nishimura K., Kataoka K., et al. Gelatin sheet incorporating basic fibroblast growth factor enhances steral healing after harvesting bilateral internal thoracic arteries. J Thorac Cardiovasc Surg 126 (2003) 1113-1120
20. Efthimiadou A., Asimakopoulos B., Nikolettos N., Giatromanolaki A., Sivridis E., Papachristou D.N., et al. Angiogenic effect of intramuscular administration of basic and acidic fibroblast growth factor on skeletal muscles and influence of exercise on muscle angiogenesis. Br J Sports Med 40 (2006) 35-39
21. Layman H., Li S., Pham S.M., and Andreopoulos F.M. Therapeutic angiogenesis in critical limb ischemia via the localized delivery of bFGF from ionic hydrogels. J Surg Res 130 (2006) 265
22. Huang N.F., Yu S.R., Li S., and Lee R.J. Injectable biopolymers enhance angiogenesis after myocardial infarction. Tissue Eng 11 (2005) 1860-1866
23. Post M.J., Laham R., Sellke F.W., and Simons M. Therapeutic angiogenesis in cardiology using protein formulations. Cardiov Res 49 (2001) 522-531
24. Young S., Wong M., Tabata Y., and Mikos A.G. Gelatin as a delivery vehicle for the controlled release of bioactive molecules. J Control Release 109 (2005) 256-274
25. Zisch A.H., Lutolf M.P., and Hubbell J.A. Biopolymeric delivery matrices for angiogenic growth factors. Cardiovasc Pathol 12 (2003) 295-310
26. Richardson T.P., Peters M.C., Ennett A.B., and Mooney D.J. Polymeric system for dual growth factor delivery. Nat Biotechnol 19 (2001) 1029-1034
27. Raymond J., Metcalfe A., Desfaits A.C., Ribourtout E., Salazkin I., Gilmartin K., et al. Alginate for endovascular treatment of aneurysms and local growth factor delivery. AJNR Am J Neuroadiol 24 (2003) 1214-1221
28. Pieper J.S., Hafmans T., van Wachem P.B., van Luyn M.J., Brouwer L.A., Veerkamp J.H., et al. Loading of collagen-heparan sulfate matricies with bFGF promotes angiogenesis and tissue regeneration in rats. J Biomed Mater Res 62 (2002) 185-194
29. Dogan A.K., Gumisderelioglu M., and Aksoz E. Controlled release of EGF and bFGF from dextran hydrogels in vitro and in vivo. J Biomed Mater Res B Appl Biomater 74 (2005) 504-510
30. Min B.M., Lee G., Kim S.H., Nam Y.S., Lee T.S., and Park W.H. Electrospinning of silk fibroin nanofibers and its effect on the adhesion and spreading of normal human keratinocytes and fibroblasts in vitro. Biomaterals 25 (2004) 1289-1297
31. 2-terminal binding repeats of the alpha subunit. J Biol Chem 275 (2000) 20324-20336
32. Rivard A., Silver M., Chen D., Kearney D., Magner M., Annex B., et al. Rescue of diabetes-related impairment of angiogenesis by intramuscular gene therapy with adeno-VEGF. Am J Pathol 154 (1999) 355-363
33. Ikada Y., and Tabata Y. Protein release from gelatin matrices. Adv Drug Deliv Rev 31 (1998) 287-301